These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 9006809)
1. Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats. Krause BR; Barnett BC; Essenburg AD; Kieft KA; Auerbach BJ; Bousley R; Stanfield R; Newton RS; Bisgaier CL Atherosclerosis; 1996 Nov; 127(1):91-101. PubMed ID: 9006809 [TBL] [Abstract][Full Text] [Related]
2. Effect of gemfibrozil on triacylglycerol synthesis and secretion by liver and lipoprotein lipase activity in adipose tissue of rats. Nagao K; Sakono M; Nakayama M; Hirakawa T; Imaizumi K Comp Biochem Physiol B Biochem Mol Biol; 1999 Nov; 124(3):289-94. PubMed ID: 10631806 [TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Krause BR; Newton RS Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869 [TBL] [Abstract][Full Text] [Related]
4. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. Bisgaier CL; Essenburg AD; Barnett BC; Auerbach BJ; Haubenwallner S; Leff T; White AD; Creger P; Pape ME; Rea TJ; Newton RS J Lipid Res; 1998 Jan; 39(1):17-30. PubMed ID: 9469582 [TBL] [Abstract][Full Text] [Related]
5. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Fruchart JC; Duriez P Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610 [TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients. Chen MF; Wang TD; Yeh HT; Hsu HC; Lee YT Eur J Clin Invest; 2001 Aug; 31(8):707-13. PubMed ID: 11473572 [TBL] [Abstract][Full Text] [Related]
7. Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats. Krause BR; Newton RS Atherosclerosis; 1986 Jan; 59(1):95-8. PubMed ID: 3081014 [TBL] [Abstract][Full Text] [Related]
8. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia. Saku K; Sasaki J; Arakawa K Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372 [TBL] [Abstract][Full Text] [Related]
9. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of gemfibrozil on lipoprotein metabolism. Saku K; Gartside PS; Hynd BA; Kashyap ML J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042 [TBL] [Abstract][Full Text] [Related]
11. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669 [TBL] [Abstract][Full Text] [Related]
12. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. Haubenwallner S; Essenburg AD; Barnett BC; Pape ME; DeMattos RB; Krause BR; Minton LL; Auerbach BJ; Newton RS; Leff T J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480 [TBL] [Abstract][Full Text] [Related]
14. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice. Inaba T; Yagyu H; Itabashi N; Tazoe F; Fujita N; Nagashima S; Okada K; Okazaki M; Furukawa Y; Ishibashi S Hypertens Res; 2008 May; 31(5):999-1005. PubMed ID: 18712055 [TBL] [Abstract][Full Text] [Related]
15. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects. Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682 [TBL] [Abstract][Full Text] [Related]
16. Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats. Maxwell RE; Nawrocki JW; Uhlendorf PD Atherosclerosis; 1983 Sep; 48(3):195-203. PubMed ID: 6579963 [TBL] [Abstract][Full Text] [Related]
17. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Dachet C; Cavallero E; Martin C; Girardot G; Jacotot B Atherosclerosis; 1995 Feb; 113(1):1-9. PubMed ID: 7755644 [TBL] [Abstract][Full Text] [Related]
18. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Kłosiewicz-Latoszek L; Szostak WB Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543 [TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats. Krause BR; Newton RS J Lipid Res; 1985 Aug; 26(8):940-9. PubMed ID: 3862732 [TBL] [Abstract][Full Text] [Related]
20. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]